Skip to main navigation
  • About
    • Our Vision
    • Our Approach
    • Our Team
  • Pipeline
    • DARE-BV1
    • OVAPRENE®
    • Sildenafil Cream, 3.6%
  • Partners
  • Consumers
  • Investors
    • Overview
    • Press Releases
    • Presentation, Events & Webcasts
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Analyst Coverage
    • Financial Information
      • Financials Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
    • Contact
  • Careers
  • Contact Us
    Dare Biosciences
    • Investors
    • Press releases
    • Presentations, Events & Webcasts
    • Stock information
    • Financial Information
    • Corporate governance
    • Contact

    Press Release

    Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

    04-17-2023 at 8:00 AM EDT
    PDF Version

    SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business Conference, hosted by Xpectives.Health, on April 20, 2023 at Westin Copley Place, Boston, MA.

    Panel:   What’s Hot and What’s Next in Women’s Health…Innovators in Women’s Health
         
    Date:   April 20, 2023
         
    Time:   4:00-4:45 p.m. Eastern Time
         
    Panelists:   Amanda Gorman, PNP, Founder, Nest Collaborative Telelactation Consultation
    Sabrina Martucci Johnson, President and CEO, Daré Bioscience
    Christine Henningsgaard, CEO, Quilted Health
    Emily Sylvester, MS, RD, LDN, IBCLC, Founder and CEO, Mother of Fact
         
    Details:   Women’s Health inventors, founders and innovators will share innovative products and services available currently, and what is in the Women’s Health product pipeline that will positively impact health care for women.
         

    For additional information on the conference, please visit https://xpectives.health/womens-health/

    About Daré Bioscience

    Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

    Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

    Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

    Contacts:

    Investors on behalf of Daré Bioscience, Inc.:
    Lee Roth
    Burns McClellan
    lroth@burnsmc.com
    212.213.0006

    OR

    Media on behalf of Daré Bioscience, Inc.:
    Jake Robison
    Evoke Canale
    jake.robison@evokegroup.com
    619.849.5383

    Source: Daré Bioscience, Inc.


    Primary Logo

    Source: Daré Bioscience, Inc.

    • Request email alerts |
    • Print this page |
    • Search investor site |

    © 2023 by Daré Bioscience | Daré Bioscience® is a registered trademark of Daré Bioscience, Inc.

    Privacy Policy | Terms of Service | COI Policy |

    Scroll to top